Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

Details

Language :

English

ISSN :

00064971 and 15280020

Volume :

140

Issue :

Supplement 1

Database :

Supplemental Index

Journal :

Blood

Publication Type :

Periodical

Accession number :

ejs61222329

Full Text :

https://doi.org/10.1182/blood-2022-163180